



EUROPEAN COMMISSION  
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

Health systems and products

**Medicinal products – authorisations, European Medicines Agency**

PHARM 688

**PHARMACEUTICAL COMMITTEE**  
**21 October 2015**

---

**Subject:** Draft agenda of the 75<sup>th</sup> meeting of the Pharmaceutical Committee  
21 October 2015, **10.00 am – 6.00 pm**

---

Venue: Centre Albert Borschette, 36, rue Froissart, Brussels, meeting room **AB-4D**.

**Welcome coffee: 9.30 am – 10.00 am**

**Lunch break: 1.00 pm – 2.30 pm**

**PHARMACEUTICAL COMMITTEE**  
**DRAFT AGENDA**  
75<sup>th</sup> meeting, 21 October 2015  
Centre Albert Borschette, Brussels, **AB-4D**

**AGENDA**

- Adoption of draft agenda

**1. INTERPRETATION OF PHARMACEUTICAL LEGISLATION**

- a) Court cases
- b) Legal and Regulatory News
- c) Variations and the use of the Article 57 database

**2. IMPLEMENTATION OF PHARMACEUTICAL LEGISLATION**

- a) Written procedure of Standing Committee – Scientific accelerated procedure
- b) Review of the 2003 Communication on orphan medicinal product
- c) Specific GMP guidelines for Advanced Therapy Medicinal Products (ATMPs)
- d) Feedback from the 2<sup>nd</sup> meeting of the Commission Expert Group on "Safe and Timely Access to Medicines for Patients" (STAMP)
- e) Clinical Trials Regulation: update on the implementation
- f) Falsified Medicines Directive: update on the implementation

**3. PHARMACOVIGILANCE**

- a) Report on the performance of pharmacovigilance tasks by the Member States and the European Medicines Agency
- b) Reports of Member States pharmacovigilance audits

#### **4. LEGISLATIVE ISSUES**

- a) Paediatrics

#### **5. INTERNATIONAL DEVELOPMENTS**

- a) Update on multilateral collaborations:

- i. The reform of the International Conference for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
- ii. International Pharmaceutical Regulators Forum (IPRF)

- b) Update on bilateral negotiations

#### **6. AOB**

- a) Summary of comments to the study reports on the Patient Information Leaflet (PIL) and the Summary of Product Characteristics (SmPC)
- b) Biosimilars: World Health Organisation (WHO) Biological Qualifier